Movatterモバイル変換

[0]ホーム
URL:

SG10201805844QA - 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase - Google Patents

1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Info

Publication number
SG10201805844QA
SG10201805844QASG10201805844QASG10201805844QASG10201805844QASG 10201805844Q ASG10201805844Q ASG 10201805844QASG 10201805844Q ASG10201805844Q ASG 10201805844QASG 10201805844Q ASG10201805844Q ASG 10201805844QASG 10201805844Q ASG10201805844Q ASG 10201805844QA
Authority
SG
Singapore
Prior art keywords
indoleamine
dioxygenase
inhibitors
oxadiazoles
oxadiazole derivatives
Prior art date
Application number
SG10201805844QA
Inventor
Andrew Combs
Eddy Yue
Richard Sparks
Wenyu Zhu
Jiacheng Zhou
Qiyan Lin
Lingkai Weng
Tai-Yuen Yue
Pingli Liu
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=41128289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201805844Q(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings CorpfiledCriticalIncyte Holdings Corp
Publication of SG10201805844QApublicationCriticalpatent/SG10201805844QA/en

Links

Classifications

Landscapes

Abstract

1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5- oxadiazole derivatives. Figure 1 accompanies the abstract
SG10201805844QA2008-07-082009-07-071,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenaseSG10201805844QA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US7887608P2008-07-082008-07-08
US15087309P2009-02-092009-02-09

Publications (1)

Publication NumberPublication Date
SG10201805844QAtrue SG10201805844QA (en)2018-08-30

Family

ID=41128289

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201805844QASG10201805844QA (en)2008-07-082009-07-071,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
SG2013052485ASG192485A1 (en)2008-07-082009-07-071,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG2013052485ASG192485A1 (en)2008-07-082009-07-071,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Country Status (36)

CountryLink
US (12)US8088803B2 (en)
EP (3)EP2315756B9 (en)
JP (2)JP5465720B2 (en)
KR (5)KR101927291B1 (en)
CN (2)CN102164902B (en)
AR (1)AR072490A1 (en)
AU (6)AU2009268739B2 (en)
BR (2)BRPI0915692B8 (en)
CA (2)CA3012229C (en)
CL (2)CL2009001554A1 (en)
CO (1)CO6341622A2 (en)
CR (1)CR11871A (en)
CY (1)CY1120617T1 (en)
DK (2)DK2315756T5 (en)
EA (2)EA022669B1 (en)
EC (1)ECSP11010798A (en)
ES (2)ES2524266T3 (en)
HR (2)HRP20141094T1 (en)
HU (1)HUE036813T2 (en)
IL (2)IL210402A (en)
LT (1)LT2824100T (en)
ME (1)ME03065B (en)
MX (1)MX2011000235A (en)
MY (3)MY171866A (en)
NO (1)NO2824100T3 (en)
NZ (1)NZ590268A (en)
PE (1)PE20110308A1 (en)
PH (1)PH12014500947B1 (en)
PL (2)PL2315756T3 (en)
PT (2)PT2315756E (en)
RS (2)RS53688B9 (en)
SG (2)SG10201805844QA (en)
SI (2)SI2315756T1 (en)
SM (2)SMT201800206T1 (en)
TW (1)TWI453204B (en)
WO (1)WO2010005958A2 (en)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
PT1879573E (en)*2005-05-102013-03-25Incyte CorpModulators of indoleamine 2,3-dioxygenase and methods of using the same
CA2634198C (en)*2005-12-202014-06-03Incyte CorporationN-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2064207B1 (en)*2006-09-192013-11-06Incyte CorporationN-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en)2006-09-192008-02-08Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
EP2315756B9 (en)*2008-07-082015-07-22Incyte Corporation1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
GB0919757D0 (en)*2009-11-122009-12-30Johnson Matthey PlcPolymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en)2009-10-152012-10-30Johnson Matthey Public Limited CompanyPolymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
NO2694640T3 (en)2011-04-152018-03-17
WO2013069765A1 (en)*2011-11-092013-05-16協和発酵キリン株式会社Nitrogenated heterocyclic compound
GB201120860D0 (en)2011-12-052012-01-18Cambridge Entpr LtdCancer immunotherapy
JP6280546B2 (en)2012-06-262018-02-14デル マー ファーマシューティカルズ Treating tyrosine kinase inhibitor resistant malignancies in patients with genetic polymorphisms or dysregulation or mutation of AHI1 using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulucitol, or analogs or derivatives thereof How to
US10034939B2 (en)2012-10-262018-07-31The University Of ChicagoSynergistic combination of immunologic inhibitors for the treatment of cancer
JP2016519684A (en)2013-04-082016-07-07デニス エム ブラウン Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects
MY174254A (en)*2013-11-082020-04-01Incyte Holdings CorpProcess for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
BR112016017700A2 (en)*2014-02-042017-10-10Incyte Corp method for treating a cancer in an individual, drug, kit, method, use or kit, and, method, drug or kit
CA2943834A1 (en)2014-03-312015-10-08Genentech, Inc.Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
EP3126394B1 (en)2014-03-312019-10-30F.Hoffmann-La Roche AgAnti-ox40 antibodies and methods of use
EP3498295A1 (en)2014-05-282019-06-19Agenus Inc.Anti-gitr antibodies and methods of use thereof
JP2017525753A (en)2014-06-062017-09-07フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． Immunomodulator
MX372995B (en)*2014-07-172020-04-13Chdi Foundation IncMethods and compositions for treating hiv-related disorders
CN105481789B (en)2014-09-152020-05-19中国科学院上海有机化学研究所Indoleamine-2,3-dioxygenase inhibitor and preparation method thereof
UY36390A (en)2014-11-052016-06-01Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN107205970A (en)2014-11-052017-09-26弗莱塞斯生物科学公司Immunomodulator
UY36391A (en)2014-11-052016-06-01Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2016100851A1 (en)2014-12-182016-06-23Lankenau Institute For Medical ResearchMethods and compositions for the treatment of retinopathy and other ocular diseases
EP3250250A4 (en)2015-01-302019-05-22President and Fellows of Harvard College PERITUMORAL AND INTRATUMORIC MATERIALS FOR ANTICANCER TREATMENT
PH12021551982A1 (en)2015-03-042022-09-05Gilead Sciences IncToll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US9873690B2 (en)*2015-03-172018-01-23Pfizer Inc3-indol substituted derivatives, pharmaceutical compositions and methods for use
WO2016155545A1 (en)*2015-03-312016-10-06江苏恒瑞医药股份有限公司Sulfamyl-containing 1,2,5-oxadiazole derivative, preparation method therefor and use thereof in pharmaceuticals
CN107709364A (en)2015-04-072018-02-16豪夫迈·罗氏有限公司Antigen binding complex and application method with agonist activity
AU2016250976B2 (en)2015-04-212020-02-27Jiangsu Hengrui Medicine Co., Ltd.Imidazo isoindole derivative, preparation method therefor and medical use thereof
CN113603784A (en)2015-05-292021-11-05艾吉纳斯公司anti-CTLA-4 antibodies and methods of use thereof
US9891882B2 (en)*2015-06-012018-02-13Nagravision S.A.Methods and systems for conveying encrypted data to a communication device
HK1252272A1 (en)2015-06-082019-05-24豪夫迈‧罗氏有限公司Methods of treating cancer using anti-ox40 antibodies
CA2988420A1 (en)2015-06-082016-12-15Genentech, Inc.Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
AU2016285483B2 (en)*2015-07-022018-07-19Glaxosmithkline Intellectual Property Development LimitedInhibitors of indoleamine 2,3-dioxygenase
EP3322444A4 (en)*2015-07-142019-06-12Kyowa Hakko Kirin Co., Ltd. A TUMOR THERAPEUTIC AGENT COMPRISING AN IDO INHIBITOR ADMINISTERED IN ASSOCIATION WITH ANTIBODY
HK1248602A1 (en)2015-07-162018-10-19Biokine Therapeutics Ltd.Compositions and methods for treating cancer
CN111004167B (en)2015-07-242024-03-22新联基因公司 Salts and prodrugs of 1-methyl-D-tryptophan
WO2017024996A1 (en)*2015-08-072017-02-16江苏恒瑞医药股份有限公司Hydroxy amidine derivative, preparation method and use in medicine thereof
AU2016312508A1 (en)2015-08-262018-02-15Gilead Sciences, Inc.Deuterated toll-like receptor modulators
MA48579A (en)2015-09-012020-03-18Agenus Inc ANTI-PD1 ANTIBODIES AND METHODS OF USING THEM
CN107396498B (en)2015-09-142019-07-23昂宝电子（上海）有限公司System and method for the current regulation in LED illumination system
CN106565696B (en)*2015-10-092020-07-28江苏恒瑞医药股份有限公司Oxadiazole derivative, preparation method and medical application thereof
KR20180095517A (en)*2015-11-042018-08-27인사이트 코포레이션 Pharmaceutical compositions and methods for the inhibition of indoleamine 2,3-dioxygenase and indications thereof
EP3374517A1 (en)2015-11-092018-09-19H. Hoffnabb-La Roche AgScreening assay to identify id01 and/or tdo modulators
TWI717432B (en)2015-12-022021-02-01美商艾吉納斯公司Antibodies and methods of use thereof
WO2017106062A1 (en)2015-12-152017-06-22Merck Sharp & Dohme Corp.Novel compounds as indoleamine 2,3-dioxygenase inhibitors
CN106883193B (en)*2015-12-152021-10-15上海翰森生物医药科技有限公司 Indoleamine 2,3-dioxygenase inhibitor and preparation method and application thereof
JP6820935B2 (en)2016-01-192021-01-27ファイザー・インク Cancer vaccine
US9624185B1 (en)*2016-01-202017-04-18Yong XuMethod for preparing IDO inhibitor epacadostat
CN105646389B (en)*2016-01-282019-06-28中国科学院上海有机化学研究所A kind of sulfamic acid rouge and its preparation method and application as indoles amine -2,3- dioxygenase inhibitor
EP3416725A1 (en)2016-02-192018-12-26INSERM (Institut National de la Santé et de la Recherche Médicale)Methods and pharmaceutical compositions for the treatment of obesity
WO2017143874A1 (en)*2016-02-252017-08-31深圳市塔吉瑞生物医药有限公司Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof
CN107176933B (en)*2016-03-092020-10-09中国科学院上海有机化学研究所Indoleamine-2,3-dioxygenase inhibitor containing nitrogen alkylated and arylated sulfoximine
CN107304191B (en)*2016-04-202023-09-29上海翰森生物医药科技有限公司Indolylamine 2,3-dioxygenase inhibitor and preparation method and application thereof
WO2017181849A1 (en)*2016-04-202017-10-26江苏豪森药业集团有限公司Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
CA3021589A1 (en)*2016-04-292017-11-02Merck Sharp & Dohme Corp.Substituted imidazopyridine compounds as inhibitors of indoleamine2,3-dioxygenase and/or tryptophan-2,3-dioxygenase
EP3452450A1 (en)2016-05-042019-03-13Bristol-Myers Squibb CompanyInhibitors of indoleamine 2,3-dioxygenase and methods of their use
ES2969239T3 (en)2016-05-272024-05-17Gilead Sciences Inc Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis B virus infections in humans
BR102017010009A2 (en)2016-05-272017-12-12Gilead Sciences, Inc. COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
SG10201912563XA (en)2016-05-272020-02-27Agenus IncAnti-tim-3 antibodies and methods of use thereof
JOP20170131B1 (en)*2016-06-102021-08-17Lilly Co Eli 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for cancer treatment
CN106109472A (en)*2016-06-132016-11-16中山大学Chlordiazepoxide is as the purposes of indole amine 2,3-dioxygenase-1 inhibitor
EP3495354A4 (en)*2016-08-022020-01-15Shandong Luye Pharmaceutical Co., Ltd.Ido1 inhibitor and preparation method and application thereof
CN109963871A (en)2016-08-052019-07-02豪夫迈·罗氏有限公司 Multivalent and multiepitopic antibodies with agonistic activity and methods of use
US20190185439A1 (en)*2016-08-242019-06-20H. Lee Moffitt Cancer Center & Research Institute, Inc.Radiofluorinated carboximidamides as ido targeting pet tracer for cancer imaging
CN109843322A (en)2016-08-262019-06-04百时美施贵宝公司The inhibitor and its application method of indole amine 2,3-dioxygenase
JOP20190024A1 (en)2016-08-262019-02-19Gilead Sciences IncSubstituted pyrrolizine compounds and uses thereof
WO2018045150A1 (en)2016-09-022018-03-08Gilead Sciences, Inc.4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
ES2906581T3 (en)2016-09-022022-04-19Gilead Sciences Inc Toll-like receptor modulator compounds
JP7358236B2 (en)2016-09-192023-10-10ユニヴァーシティ オブ サウス フロリダ How to target oncolytic viruses to tumors
EP3526256A1 (en)2016-10-112019-08-21Agenus Inc.Anti-lag-3 antibodies and methods of use thereof
CA3037387A1 (en)2016-10-132018-04-19Juno Therapeutics, Inc.Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
PE20191353A1 (en)2016-10-142019-10-01Prec Biosciences Inc SPECIFICALLY DESIGNED MEGANUCLEASES FOR SEQUENCE RECOGNITION IN THE HEPATITIS B VIRUS GENOME
CN107954999B (en)*2016-10-172023-01-24上海医药集团股份有限公司Oxadiazole ring-containing compound, preparation method, intermediate, composition and application
WO2018081648A2 (en)2016-10-292018-05-03Genentech, Inc.Anti-mic antibidies and methods of use
UY37466A (en)2016-11-032018-01-31Phenex Discovery Verwaltungs Gmbh N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
AU2017359467A1 (en)2016-11-092019-05-02Agenus Inc.Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
EP3544965A4 (en)*2016-11-282020-05-20Shanghai Fochon Pharmaceutical Co., Ltd.Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
IL266918B2 (en)2016-12-072024-03-01Agenus Inc Anti-CTLA-4 antibodies and methods of using them
AU2017373945B2 (en)2016-12-072025-01-23Agenus Inc.Antibodies and methods of use thereof
EP3842442B1 (en)2016-12-222023-11-01Precision Pharmaceuticals, Inc.Compositions and methods for inhibiting arginase activity
CN108218807A (en)2016-12-222018-06-29上海长森药业有限公司A kind of sulfone amidine as indoles amine -2,3- dioxygenase inhibitors and its preparation method and application
KR20190103226A (en)2017-01-132019-09-04아게누스 인코포레이티드 T cell receptor that binds to NY-ESO-1 and methods of use thereof
CA3047002A1 (en)2017-01-172018-07-26Board Of Regents, The University Of Texas SystemCompounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
AR110768A1 (en)2017-01-312019-05-02Gilead Sciences Inc CRYSTAL FORMS OF TENOFOVIR ALAFENAMIDA
JOP20180008A1 (en)2017-02-022019-01-30Gilead Sciences IncCompounds for the treatment of hepatitis b virus infection
US11034661B2 (en)2017-03-292021-06-15Merck Sharp & Dohme Corp.Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors
US11439623B2 (en)2017-04-042022-09-13Case Western Reserve UniversityMethod of modulating ribonucleotide reductase
CN108689958B (en)*2017-04-052021-09-17南京华威医药科技集团有限公司Indoleamine 2,3-dioxygenase inhibitor containing hydrazino
CN106967005B (en)*2017-04-072019-07-16上海肇钰医药科技有限公司A kind of compound that can inhibit IDO, Its Preparation Method And Use
CN110546166B (en)2017-04-132024-03-29艾吉纳斯公司anti-CD 137 antibodies and methods of use thereof
JOP20180040A1 (en)2017-04-202019-01-30Gilead Sciences IncPd-1/pd-l1 inhibitors
CN114920710B (en)*2017-04-272024-09-20鲁南制药集团股份有限公司Imido urea derivatives
PT3618863T (en)2017-05-012023-08-23Agenus IncAnti-tigit antibodies and methods of use thereof
CN109081818B (en)*2017-06-142022-04-22南京华威医药科技集团有限公司Novel indoleamine 2, 3-bis-oxidase inhibitors
CN109111438B (en)*2017-06-262021-11-02正大天晴药业集团股份有限公司Amidine compounds for IDO inhibitors
KR20200027551A (en)2017-07-112020-03-12화이자 인코포레이티드 Immunogenic composition comprising CEA MUC1 and TERT
JP7368856B2 (en)2017-07-252023-10-25トゥルーバインディング，インコーポレイテッド Cancer treatment by blocking the interaction between TIM-3 and its ligand
US11267824B2 (en)2017-08-172022-03-08Idorsia Pharmaceuticals LtdInhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
CN107311956A (en)*2017-08-222017-11-03合肥圣迪利克医药科技有限公司One kind Chinese mugwort card, which is stamped, takes charge of his synthetic method
AU2018326875A1 (en)2017-09-042020-03-19Agenus Inc.T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
CN108863976B (en)*2017-09-112022-09-16郑州泰基鸿诺医药股份有限公司Compounds useful as IDO modulators and uses thereof
CN111328280A (en)2017-09-112020-06-23阿托萨治疗学公司 Methods of making and using nexifene
JP2020534289A (en)2017-09-142020-11-26ランケナー インスティテュート フォー メディカル リサーチ Methods and compositions for the treatment of cancer
WO2019057104A1 (en)*2017-09-202019-03-28上海翰森生物医药科技有限公司Salt of dioxygenase inhibitor and preparation method therefor and use thereof
CN109897011B (en)*2017-12-082023-10-31上海华汇拓医药科技有限公司IDO inhibitor and application thereof
CN109928922A (en)*2017-12-182019-06-25成都华健未来科技有限公司A kind of cyclohexanes compound
CN109942565B (en)2017-12-202021-03-26海创药业股份有限公司Indoleamine-2, 3-dioxygenase inhibitor and preparation method and application thereof
EP3728282B1 (en)2017-12-202023-11-22Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (en)2017-12-202022-03-16インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． 3'3'cyclic dinucleotide with phosphonate binding that activates the STING adapter protein
JP2021509669A (en)2018-01-052021-04-01ディセルナ ファーマシューティカルズ インコーポレイテッド Reduced expression of beta-catenin and IDO to enhance immunotherapy
ES2907282T3 (en)2018-01-152022-04-22Idorsia Pharmaceuticals Ltd Indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase inhibitors
CN108586378B (en)2018-01-222020-06-19南京华威医药科技集团有限公司Indoleamine 2, 3-bis-oxidase inhibitor and preparation method and application thereof
GB2585149B (en)*2018-01-242022-06-01Nanjing Carephar Shenghui Pharmaceutical Co LtdModulator of indoleamine-(2.3)-dioxygenase, preparation method and use thereof
CN110066253B (en)*2018-01-242023-06-23江苏柯菲平医药股份有限公司1,2, 5-oxadiazole derivative, preparation method thereof and application thereof in medicines
CN110577501A (en)*2018-06-072019-12-17江苏柯菲平医药股份有限公司indoleamine 2, 3-dioxygenase modulators, method for the production and use thereof
EP3747875B1 (en)2018-02-022022-12-07Hinova Pharmaceuticals Inc.Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof
CN108101899B (en)*2018-02-112021-01-26中国药科大学Preparation method of intermediate of IDO1 inhibitor Epacadostat
IL300572A (en)2018-02-132023-04-01Gilead Sciences IncPd-1/pd-l1 inhibitors
US10836769B2 (en)2018-02-262020-11-17Gilead Sciences, Inc.Substituted pyrrolizine compounds and uses thereof
WO2019195181A1 (en)2018-04-052019-10-10Gilead Sciences, Inc.Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (en)2018-04-062023-10-11捷克科學院有機化學與生物化學研究所2'3'-cyclic dinucleotides
TWI833744B (en)2018-04-062024-03-01捷克科學院有機化學與生物化學研究所3'3'-cyclic dinucleotides
TW202005654A (en)2018-04-062020-02-01捷克科學院有機化學與生物化學研究所2'2'-cyclic dinucleotides
TW201945388A (en)2018-04-122019-12-01美商精密生物科學公司Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome
US20190314324A1 (en)2018-04-132019-10-17The University Of ChicagoCombination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
TWI712412B (en)2018-04-192020-12-11美商基利科學股份有限公司Pd-1/pd-l1 inhibitors
KR20210005646A (en)2018-04-262021-01-14아게누스 인코포레이티드 Heat shock protein-binding peptide composition and method for use thereof
CN110407765B (en)*2018-04-282022-12-06上海挚盟医药科技有限公司1,2,5-oxadiazole derivative, preparation method and medical application thereof
WO2019211799A1 (en)2018-05-032019-11-07Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
GB201809050D0 (en)2018-06-012018-07-18E Therapeutics PlcModulators of tryptophan catabolism
PT3820572T (en)2018-07-132023-11-10Gilead Sciences IncPd-1/pd-l1 inhibitors
WO2020018670A1 (en)2018-07-172020-01-23Board Of Regents, The University Of Texas SystemCompounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020028097A1 (en)2018-08-012020-02-06Gilead Sciences, Inc.Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN109180603A (en)*2018-10-102019-01-11中国药科大学The preparation method of Epacadostat key intermediate
US11236085B2 (en)2018-10-242022-02-01Gilead Sciences, Inc.PD-1/PD-L1 inhibitors
JP7460644B2 (en)2018-10-312024-04-02ギリアード サイエンシーズ， インコーポレイテッド Substituted 6-Azabenzimidazole Compounds as HPK1 Inhibitors
WO2020092528A1 (en)2018-10-312020-05-07Gilead Sciences, Inc.Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CN111617078B (en)*2019-02-282023-02-03四川科伦博泰生物医药股份有限公司Pharmaceutical compositions, methods and uses thereof for the treatment and/or prevention of disease
EP3935065A1 (en)2019-03-072022-01-12Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3129011C (en)2019-03-072023-12-19Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.3'3'-cyclic dinucleotides and prodrugs thereof
CA3129022C (en)2019-03-072023-08-01Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.2'3'-cyclic dinucleotides and prodrugs thereof
TWI751516B (en)2019-04-172022-01-01美商基利科學股份有限公司Solid forms of a toll-like receptor modulator
TWI751517B (en)2019-04-172022-01-01美商基利科學股份有限公司Solid forms of a toll-like receptor modulator
EP3972695A1 (en)2019-05-232022-03-30Gilead Sciences, Inc.Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3140708A1 (en)2019-06-182020-12-24Helen HortonCombination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
CA3142513A1 (en)2019-06-252020-12-30Gilead Sciences, Inc.Flt3l-fc fusion proteins and methods of use
KR20220042352A (en)2019-07-032022-04-05아토사 테라퓨틱스, 인크. Endoxifen sustained-release composition
CN110204537B (en)*2019-07-102021-10-08盛世泰科生物医药技术(苏州)有限公司1,2, 5-oxadiazole derivatives as inhibitors of indoleamine 2, 3-dioxygenase
CA3146406A1 (en)2019-07-112021-01-14Idorsia Pharmaceuticals LtdInhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2021011891A1 (en)2019-07-182021-01-21Gilead Sciences, Inc.Long-acting formulations of tenofovir alafenamide
AU2020319875A1 (en)2019-08-012022-02-17Incyte CorporationA dosing regimen for an IDO inhibitor
WO2021034804A1 (en)2019-08-192021-02-25Gilead Sciences, Inc.Pharmaceutical formulations of tenofovir alafenamide
WO2021042019A1 (en)2019-08-302021-03-04Agenus Inc.Anti-cd96 antibodies and methods of use thereof
TWI755055B (en)*2019-09-182022-02-11台灣神隆股份有限公司Process for preparing elagolix sodium and intermediates thereof
PE20221111A1 (en)2019-09-302022-07-11Gilead Sciences Inc HBV VACCINES AND HBV TREATMENT METHODS
KR20220100904A (en)2019-11-122022-07-18남미 테라퓨틱스, 인크. Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful for the treatment of cancer and methods thereof
DK4069729T3 (en)2019-12-062025-04-07Prec Biosciences Inc OPTIMIZED, MODIFIED MEGANUCLEASES WITH SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
CN113045655A (en)2019-12-272021-06-29高诚生物医药(香港)有限公司anti-OX 40 antibodies and uses thereof
EP4121437A1 (en)2020-03-202023-01-25Gilead Sciences, Inc.Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN116157151A (en)2020-05-262023-05-23真和制药有限公司Methods of treating inflammatory diseases by blocking galectin-3
PE20230779A1 (en)2020-08-072023-05-09Gilead Sciences Inc PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE
WO2022064526A1 (en)*2020-09-252022-03-31Msn Laboratories Private Limited, R&D CenterSolid state forms of epacadostat and their processes for preparation thereof
TWI815194B (en)2020-10-222023-09-11美商基利科學股份有限公司INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
EP4052705A1 (en)2021-03-052022-09-07Universität Basel Vizerektorat ForschungCompositions for the treatment of ebv associated diseases or conditions
WO2022184930A2 (en)2021-03-052022-09-09Universität BaselCompositions for the treatment of ebv associated diseases or conditions
TW202348237A (en)2021-05-132023-12-16美商基利科學股份有限公司Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
WO2022271677A1 (en)2021-06-232022-12-29Gilead Sciences, Inc.Diacylglyercol kinase modulating compounds
AU2022298639B2 (en)2021-06-232024-11-07Gilead Sciences, Inc.Diacylglyercol kinase modulating compounds
EP4359415A1 (en)2021-06-232024-05-01Gilead Sciences, Inc.Diacylglyercol kinase modulating compounds
US11926628B2 (en)2021-06-232024-03-12Gilead Sciences, Inc.Diacylglyercol kinase modulating compounds
GB202303250D0 (en)2023-03-062023-04-19King S College LondonMethod and compounds
CN119841748B (en)*2025-03-212025-06-10济南大学 A kind of preparation method of toluenesulfonylurea

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3236855A (en)1964-01-171966-02-22Merck & Co IncCertain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en)1964-02-191967-11-21Sterling Drug Inc1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
US3553228A (en)1967-09-261971-01-05Colgate Palmolive Co3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (en)1970-08-171972-02-24Fahlberg List VebSubstd hydroxyguanidines prepn
US3948928A (en)1972-03-171976-04-06Dainippon Pharmaceutical Co., Ltd.3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (en)1973-09-051981-05-16
DD128918A5 (en)1975-09-111977-12-21Philagro Sa PHYTHOHORMONAL AND HERBICIDAL COMPOSITIONS
FR2323683A1 (en)1975-09-111977-04-08Philagro SaPhytohormonal and herbicidal amidoxime derivs. - prepd. by treatment of an imino ether with an O-amino oxy-acetate
US4399216A (en)1980-02-251983-08-16The Trustees Of Columbia UniversityProcesses for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)1980-02-251993-01-12The Trustees Of Columbia University In The City Of New YorkProcesses for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)1980-02-251987-01-06The Trustees Of Columbia University In The City Of New YorkProcesses for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4323681A (en)1980-09-291982-04-06American Home Products Corporation4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
US5156840A (en)1982-03-091992-10-20Cytogen CorporationAmine-containing porphyrin derivatives
JPS58208275A (en)1982-05-201983-12-03Lion Corp5-amino-pyrazole derivative and antitumor agent containing it
EP0132680B1 (en)1983-07-221987-01-28Bayer AgSubstituted furazans
US4507485A (en)1984-01-231985-03-26Bristol-Myers Company3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (en)1984-03-131985-10-02Toyo Jozo Co LtdImidazoleamidoxime having cyclopentene ring and its preparation
JPS6259283A (en)1985-09-101987-03-14Kaken Pharmaceut Co LtdCephalosporin compound
US5057313A (en)1986-02-251991-10-15The Center For Molecular Medicine And ImmunologyDiagnostic and therapeutic antibody conjugates
JPS6320710A (en)1986-07-111988-01-28Matsushita Electric Ind Co LtdProduction of thin film magnetic head
DE3883899T3 (en)1987-03-181999-04-22Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
JP2696342B2 (en)1988-06-271998-01-14日本曹達株式会社 Amidine derivative, method for producing the same, acaricide and agricultural / horticultural fungicide
ES2051986T3 (en)1988-07-051994-07-01Akzo Nv COMPOUNDS WITH BRONCHODILATING ACTIVITY.
IL162181A (en)1988-12-282006-04-10Pdl Biopharma IncA method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
DE3920358A1 (en)1989-06-221991-01-17Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5859205A (en)1989-12-211999-01-12Celltech LimitedHumanised antibodies
JPH04297449A (en)1991-03-271992-10-21Hokko Chem Ind Co Ltd N-hydroxybenzylguanidine derivatives and agricultural and horticultural fungicides
JPH05186458A (en)1991-04-261993-07-27Japan Tobacco Inc Novel benzopyran derivative
FR2677019B1 (en)1991-05-271994-11-25Pf Medicament NOVEL PIPERIDINES DISUBSTITUEES-1,4, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
WO1992022653A1 (en)1991-06-141992-12-23Genentech, Inc.Method for making humanized antibodies
EP0617706B1 (en)1991-11-252001-10-17Enzon, Inc.Multivalent antigen-binding proteins
US5714350A (en)1992-03-091998-02-03Protein Design Labs, Inc.Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en)1992-04-031996-05-28Ciba-Geigy CorporationPyrimidine derivatives and processes for the preparation thereof
JP2709677B2 (en)1992-06-191998-02-04株式会社大塚製薬工場 Phosphonic acid diester derivatives
SI9200344B (en)1992-11-261998-06-30Lek, A process for the preparation of amlodipine benzenesulfonate
US5827690A (en)1993-12-201998-10-27Genzyme Transgenics CorporatiionTransgenic production of antibodies in milk
FR2720396B1 (en)1994-05-271996-06-28Adir New N-pyridyl carboxamides and derivatives, their preparation process and the pharmaceutical compositions containing them.
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
US5869046A (en)1995-04-141999-02-09Genentech, Inc.Altered polypeptides with increased half-life
US5731315A (en)1995-06-071998-03-24Rhone-Poulenc Rorer Pharmaceuticals Inc.Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
ES2176484T3 (en)1995-08-182002-12-01Morphosys Ag PROTEIN BANKS / (POLI) PEPTIDES.
US5883102A (en)1995-10-171999-03-16Astra Pharmaceuticals LimitedPharmaceutically active compounds
AU1730497A (en)1996-02-171997-09-02Agrevo Uk LimitedFungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en)1996-05-031999-09-21Hoffmann-La Roche Inc.Method of treating diseases of the CNS
JPH11171702A (en)1997-09-241999-06-29Takeda Chem Ind LtdPest controlling method
US6451840B1 (en)1997-12-052002-09-17Medical College Of Georgia Research Institute, Inc.Regulation of T cell-mediated immunity by tryptophan
HUP0102415A3 (en)1997-12-102002-03-28Dainippon Ink & ChemicalsOxime derivatives, intermediates, preparation thereof and agricultural chemicals containing the same
AR018424A1 (en)1998-06-022001-11-14Sumitomo Chem Takeda Agro Co OXADIAZOLINE COMPOUND, AGROCHEMICAL COMPOSITION THAT UNDERSTANDS IT AND USES ITSELF FOR THE PREPARATION OF SUCH COMPOSITION
CN1152031C (en)1998-08-112004-06-02诺瓦提斯公司Isoquinoline derivatives with angiogenesis inhibiting activity
FR2784678B1 (en)1998-09-232002-11-29Sod Conseils Rech Applic NOVEL N- (IMINOMETHYL) AMINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6133031A (en)1999-08-192000-10-17Isis Pharmaceuticals Inc.Antisense inhibition of focal adhesion kinase expression
EP1075469B1 (en)1999-03-032004-05-26Samjin Pharmaceutical Co., Ltd.Piperazine derivatives and process for the preparation thereof
GB9905075D0 (en)1999-03-061999-04-28Zeneca LtdChemical compounds
WO2000061609A2 (en)1999-04-092000-10-19Basf AktiengesellschaftProdrugs of thrombin inhibitors
CN1164574C (en)1999-05-242004-09-01三菱制药株式会社Phenoxypropylamine compounds
JP2001158786A (en)1999-11-302001-06-12Takeda Chem Ind LtdController against mammalian ectoparasite
JP2001158785A (en)1999-11-302001-06-12Takeda Chem Ind LtdAgrochemical composition
WO2001051456A2 (en)2000-01-132001-07-19Tularik Inc.Antibacterial agents
JP2001233861A (en)2000-02-222001-08-28Ube Ind Ltd Pyrazole oxime compounds, their production and use
GB0004890D0 (en)2000-03-012000-04-19Astrazeneca Uk LtdChemical compounds
PT1294358E (en)2000-06-282004-12-31Smithkline Beecham Plc MOORING PROCESS BY HUMIDITY
NZ525614A (en)*2000-12-182005-03-24Actelion Pharmaceuticals LtdNovel sulfamides and their use as endothelin receptor antagonists
GB0108102D0 (en)2001-03-302001-05-23Pfizer LtdCompounds
PL367275A1 (en)2001-06-182005-02-21Applied Research Systems Ars Holding N.V.Pyrrolidine oxadiazole- and thiadiazole derivatives
WO2003024967A2 (en)2001-09-192003-03-27Aventis Pharma S.A.Indolizines as kinase protein inhibitors
DE60213842T2 (en)2001-10-302007-09-06Novartis Ag STAUROSPORINE DERIVATIVES AS INHIBITORS OF THE FLT3 RECEPTOR TYROSINE KINASE EFFECT
EA007395B3 (en)2002-01-222018-02-28Уорнер-Ламберт Компани Ллс2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3-d]PYRIMIDIN-7-ONES
DE60311567T2 (en)2002-02-192007-10-31Pfizer Italia S.R.L. TRICYCLIC PYRAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTITUMOR AGENTS
CA2477967C (en)*2002-03-052010-08-10Eli Lilly And CompanyPurine derivatives as kinase inhibitors
GB0208224D0 (en)2002-04-102002-05-22Celltech R&D LtdChemical compounds
CA2483451C (en)2002-04-122014-07-29Medical College Of Georgia Research Institute, Inc.Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
BR0311419A (en)2002-05-282005-04-05Dimensional Pharm Inc Thiophene amidines, their compositions and methods for treating complement-mediated diseases and conditions
PE20040522A1 (en)2002-05-292004-09-28Novartis Ag DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE
GB0215676D0 (en)2002-07-052002-08-14Novartis AgOrganic compounds
US7157462B2 (en)2002-09-242007-01-02Euro-Celtique S.A.Therapeutic agents useful for treating pain
US7015321B2 (en)2002-10-122006-03-21The Scripps Research InstituteSynthesis of non-symmetrical sulfamides using burgess-type reagents
AR042052A1 (en)2002-11-152005-06-08Vertex Pharma USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES
UA80767C2 (en)2002-12-202007-10-25Pfizer Prod IncPyrimidine derivatives for the treatment of abnormal cell growth
JP2006524039A (en)2003-01-092006-10-26マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
WO2004065416A2 (en)2003-01-162004-08-05Genentech, Inc.Synthetic antibody phage libraries
WO2004072266A2 (en)2003-02-132004-08-26Kalobios Inc.Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en)2003-03-142003-04-23Novartis AgOrganic compounds
CA2520586C (en)2003-03-272011-06-14Lankenau Institute For Medical ResearchNovel ido inhibitors and methods of use
US7598287B2 (en)2003-04-012009-10-06Medical College Of Georgia Research Institute, Inc.Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
NZ544486A (en)2003-06-132009-04-30Biogen Idec IncAglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US7157476B2 (en)2003-08-202007-01-02Vertex Pharmaceuticals IncorporatedAminofurazan compounds useful as protein kinase inhibitors
AU2004266159A1 (en)2003-08-222005-03-03Biogen Idec Ma Inc.Improved antibodies having altered effector function and methods for making the same
AR045944A1 (en)2003-09-242005-11-16Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
DE10348022A1 (en)2003-10-152005-05-25Imtm Gmbh New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
DE10348023A1 (en)2003-10-152005-05-19Imtm Gmbh New alanyl aminopeptidase inhibitors for the functional manipulation of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
MY144044A (en)2004-06-102011-07-29Irm LlcCompounds and compositions as protein kinase inhibitors
ES2396419T3 (en)2004-09-082013-02-21Mitsubishi Tanabe Pharma Corporation Morpholine compounds for the treatment of inflammations
WO2006056399A2 (en)2004-11-242006-06-01Novartis AgCombinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
JP5065908B2 (en)2004-12-242012-11-07プロシディオン・リミテッド G protein-coupled receptor agonist
US7429667B2 (en)2005-01-202008-09-30Ardea Biosciences, Inc.Phenylamino isothiazole carboxamidines as MEK inhibitors
EP2439273B1 (en)*2005-05-092019-02-27Ono Pharmaceutical Co., Ltd.Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PT1879573E (en)2005-05-102013-03-25Incyte CorpModulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2006133417A1 (en)2005-06-072006-12-14Valeant Pharmaceuticals InternationalPhenylamino isothiazole carboxamidines as mek inhibitors
EP1901789A2 (en)2005-06-302008-03-26Anthrogenesis CorporationRepair of tympanic membrane using placenta derived collagen biofabric
DE102005060466A1 (en)2005-12-172007-06-28Bayer Cropscience Ag carboxamides
CA2634198C (en)2005-12-202014-06-03Incyte CorporationN-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20070203140A1 (en)2006-02-092007-08-30Combs Andrew PN-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (en)2006-05-122009-07-15株式会社サクラクレパス India ink
EP2064207B1 (en)2006-09-192013-11-06Incyte CorporationN-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (en)2006-09-192008-02-08Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
WO2008036652A2 (en)*2006-09-192008-03-27Incyte CorporationAmidines as modulators of indoleamine 2,3-dioxygenase
US20080119491A1 (en)2006-09-192008-05-22Incyte CorporationAmidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008058178A1 (en)*2006-11-082008-05-15Incyte CorporationN-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7998995B2 (en)2006-12-082011-08-16Exelixis Patent Company LlcLXR and FXR modulators
TW200845991A (en)2007-01-122008-12-01Smithkline Beecham CorpN-substituted glycine derivatives: hydroxylase inhibitors
BRPI0821209A2 (en)2007-12-192019-09-24Amgen Inc compound, pharmaceutical composition, methods of treating cancer, reducing tumor size, treating disorders, and reducing metastasis in a tumor.
EP2219646A4 (en)2007-12-212010-12-22Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
EP2315756B9 (en)*2008-07-082015-07-22Incyte Corporation1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
JO2885B1 (en)2008-12-222015-03-15ايلي ليلي اند كومبانيProtein kinase inhibitors
UY33227A (en)2010-02-192011-09-30Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
CA2961937C (en)2010-10-252018-09-25G1 Therapeutics, Inc.Cdk inhibitors
AU2012230896B9 (en)2011-03-232015-06-18Amgen Inc.Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US10034939B2 (en)2012-10-262018-07-31The University Of ChicagoSynergistic combination of immunologic inhibitors for the treatment of cancer
MY174254A (en)2013-11-082020-04-01Incyte Holdings CorpProcess for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
BR112016017700A2 (en)2014-02-042017-10-10Incyte Corp method for treating a cancer in an individual, drug, kit, method, use or kit, and, method, drug or kit
EP3200775B1 (en)2014-10-032019-11-20Novartis AGCombination therapies
SI3456346T1 (en)2015-07-302021-11-30Macrogenics, Inc. PD-1 and LAG-3 binding molecules and methods for their use
BR112018004069A2 (en)2015-09-012021-07-13First Wave Bio, Inc. solid pharmaceutical composition, enema preparation comprising niclosamide, enema formulation, use of niclosamide and kit
KR20180095517A (en)2015-11-042018-08-27인사이트 코포레이션 Pharmaceutical compositions and methods for the inhibition of indoleamine 2,3-dioxygenase and indications thereof
JP2018020710A (en)2016-08-052018-02-08三井造船株式会社 Ship rudder and ship
JP2021509669A (en)2018-01-052021-04-01ディセルナ ファーマシューティカルズ インコーポレイテッド Reduced expression of beta-catenin and IDO to enhance immunotherapy
AU2020319875A1 (en)2019-08-012022-02-17Incyte CorporationA dosing regimen for an IDO inhibitor

Also Published As

Publication numberPublication date
BRPI0915692B1 (en)2019-12-03
BRPI0915692B8 (en)2021-05-25
CA3012229A1 (en)2010-01-14
IL210402A (en)2015-02-26
JP2014114299A (en)2014-06-26
KR101783004B1 (en)2017-09-28
EA201170161A1 (en)2011-08-30
CN102164902B (en)2014-07-23
US20140023663A1 (en)2014-01-23
MY171866A (en)2019-11-05
PT2315756E (en)2014-12-16
US10034864B2 (en)2018-07-31
CL2009001554A1 (en)2009-10-30
PH12014500947B1 (en)2019-03-01
ES2524266T9 (en)2015-10-05
US20170348289A1 (en)2017-12-07
CA2743975A1 (en)2010-01-14
HUE036813T2 (en)2018-07-30
US20220331296A1 (en)2022-10-20
TWI453204B (en)2014-09-21
IL210402A0 (en)2011-03-31
AR072490A1 (en)2010-09-01
EP2315756A2 (en)2011-05-04
PL2824100T3 (en)2018-07-31
US9789094B2 (en)2017-10-17
US20150190378A1 (en)2015-07-09
BR122019015876B1 (en)2020-03-10
ES2665419T3 (en)2018-04-25
US11207302B2 (en)2021-12-28
KR20180133538A (en)2018-12-14
PH12014500947A1 (en)2015-03-30
CA2743975C (en)2018-09-11
DK2315756T5 (en)2015-08-03
CN102164902A (en)2011-08-24
US10653677B2 (en)2020-05-19
BR122019015876B8 (en)2021-07-27
EA201500530A1 (en)2015-08-31
US10369137B2 (en)2019-08-06
AU2014210662A1 (en)2014-08-28
RS53688B9 (en)2020-01-31
US9320732B2 (en)2016-04-26
CL2014000363A1 (en)2014-08-01
ECSP11010798A (en)2011-03-31
US20240173303A1 (en)2024-05-30
IL235870A0 (en)2015-01-29
KR101847107B1 (en)2018-04-10
CO6341622A2 (en)2011-11-21
EP2315756B9 (en)2015-07-22
TW201006827A (en)2010-02-16
CN104042611A (en)2014-09-17
MY192633A (en)2022-08-29
DK2315756T3 (en)2014-10-13
CY1120617T1 (en)2019-12-11
SG192485A1 (en)2013-08-30
RS53688B1 (en)2015-04-30
AU2018200457A1 (en)2018-02-08
US8088803B2 (en)2012-01-03
KR20110031971A (en)2011-03-29
HK1157692A1 (en)2012-07-06
AU2018267589B2 (en)2020-06-25
JP5819451B2 (en)2015-11-24
IL235870A (en)2016-05-31
SI2824100T1 (en)2018-06-29
KR20170113707A (en)2017-10-12
AU2009268739B2 (en)2014-05-08
KR20180037325A (en)2018-04-11
US8822511B2 (en)2014-09-02
WO2010005958A3 (en)2010-06-24
CA3012229C (en)2020-11-10
EP2315756B1 (en)2014-09-03
AU2020239772B2 (en)2022-09-15
EP2824100A1 (en)2015-01-14
KR101649548B1 (en)2016-08-19
NZ590268A (en)2012-11-30
KR101927291B1 (en)2018-12-10
US20120058079A1 (en)2012-03-08
HK1206029A1 (en)2015-12-31
MX2011000235A (en)2011-02-23
SMT201800206T1 (en)2018-05-02
AU2009268739A1 (en)2010-01-14
EP2824100B1 (en)2018-02-21
EA022669B1 (en)2016-02-29
LT2824100T (en)2018-05-10
KR102031538B1 (en)2019-11-08
US8796319B2 (en)2014-08-05
EA029781B1 (en)2018-05-31
EP3360873A1 (en)2018-08-15
KR20160110969A (en)2016-09-23
DK2824100T3 (en)2018-04-16
PL2315756T3 (en)2015-02-27
CN104042611B (en)2019-05-14
WO2010005958A2 (en)2010-01-14
JP2011527686A (en)2011-11-04
SMT201400179B (en)2015-01-15
AU2018267589A1 (en)2018-12-06
HRP20141094T1 (en)2015-01-16
US8993605B2 (en)2015-03-31
HRP20180662T1 (en)2018-06-01
US20160220543A1 (en)2016-08-04
PT2824100T (en)2018-05-10
US20180177769A1 (en)2018-06-28
NO2824100T3 (en)2018-07-21
JP5465720B2 (en)2014-04-09
ME03065B (en)2019-01-20
AU2020239772A1 (en)2020-10-22
CR11871A (en)2011-03-30
US20190298700A1 (en)2019-10-03
PE20110308A1 (en)2011-06-10
SI2315756T1 (en)2014-12-31
US20140315962A1 (en)2014-10-23
AU2016204914A1 (en)2016-08-04
MY177058A (en)2020-09-03
US20100015178A1 (en)2010-01-21
ES2524266T3 (en)2014-12-04
RS57132B1 (en)2018-07-31
US20210030722A1 (en)2021-02-04

Similar Documents

PublicationPublication DateTitle
SG10201805844QA (en)1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CA2871471C (en)Dna-pk inhibitors
EP2170337A4 (en)Novel triazolopyridazines
PH12014502772A1 (en)Substituted tricyclic compounds as fgfr inhibitors
GEP20135785B (en)Pyrrolopyrimidine compounds as cdk inhibitors
EA201101650A1 (en) NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF MALIGNANT NONFORMS AND THE FOLLOWING DISEASES
UA101493C2 (en)Azetidine and cyclobutane derivatives as jak inhibitors
UA108743C2 (en) HINAZOLINE-4 (3H) -ONE DERIVATIVES FOR APPLICATION AS RI-KINASE INHIBITORS
MX2011006006A (en)Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
CA2818187C (en)Bromodomain inhibitors and uses thereof
IN2012DN03883A (en)
EA201001143A1 (en) ACTIVATORS OF THE PERFORMERS "EXECUTORS" 3, 6 And 7
WO2007095050A3 (en)N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
EA201291099A1 (en) NEW IMMUNODULATOR AND ANTI-INFLAMMATORY CONNECTIONS
MX2011013032A (en)Inhibitors of phosphatidylinositol 3-kinase.
AU2009319796A8 (en)Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers
MX2012000178A (en)2-carboxamide cycloamino ureas useful as pi3k inhibitors.
MX2011008645A (en)Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase.
MX2011012524A (en)Inhibitors of c-met protein kinase.
MX2011012522A (en)Substituted pyrazole inhibitors of c-met protein kinase.
MX2011013324A (en)Use of substituted oxindole derivatives for the treatment and prophylaxis of pain.
WO2009126335A3 (en)Ant2 inhibitor compounds and methods of use thereof
WO2009151495A3 (en)Oxazole compounds, compositions and methods of use
UA105010C2 (en)1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EA201890183A1 (en) 1,2,5-OXADIAZOLES AS INDOLAMIN-2,3-DIOXYGENASE INHIBITORS
[8]ページ先頭
©2009-2025 Movatter.jp